580 related articles for article (PubMed ID: 9605165)
1. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
2. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
3. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
4. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
[TBL] [Abstract][Full Text] [Related]
5. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
6. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
7. Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.
Kumar J; Yadav VN; Phulera S; Kamble A; Gautam AK; Panwar HS; Sahu A
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724763
[TBL] [Abstract][Full Text] [Related]
8. Regulation of complement activity by vaccinia virus complement-control protein.
McKenzie R; Kotwal GJ; Moss B; Hammer CH; Frank MM
J Infect Dis; 1992 Dec; 166(6):1245-50. PubMed ID: 1431243
[TBL] [Abstract][Full Text] [Related]
9. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
Medicus RG; Melamed J; Arnaout MA
Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
[TBL] [Abstract][Full Text] [Related]
10. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
Medof ME; Nussenzweig V
J Exp Med; 1984 Jun; 159(6):1669-85. PubMed ID: 6233387
[TBL] [Abstract][Full Text] [Related]
11. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
13. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
Fries LF; Prince GM; Gaither TA; Frank MM
J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
[TBL] [Abstract][Full Text] [Related]
14. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
Koistinen V; Wessberg S; Leikola J
Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
[TBL] [Abstract][Full Text] [Related]
15. Domain swapping reveals complement control protein modules critical for imparting cofactor and decay-accelerating activities in vaccinia virus complement control protein.
Ahmad M; Raut S; Pyaram K; Kamble A; Mullick J; Sahu A
J Immunol; 2010 Nov; 185(10):6128-37. PubMed ID: 20956343
[TBL] [Abstract][Full Text] [Related]
16. Proposed structure of the F' allotype of human CR1. Loss of a C3b binding site may be associated with altered function.
Wong WW; Farrell SA
J Immunol; 1991 Jan; 146(2):656-62. PubMed ID: 1670949
[TBL] [Abstract][Full Text] [Related]
17. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
Kinoshita T; Lavoie S; Nussenzweig V
J Immunol; 1985 Apr; 134(4):2564-70. PubMed ID: 3156184
[TBL] [Abstract][Full Text] [Related]
18. Glomerular CR1 express in situ cofactor activity for degradation of C3b.
Vedeler CA; Matre R; Iversen BM
Int Arch Allergy Appl Immunol; 1990; 92(1):60-3. PubMed ID: 2147176
[TBL] [Abstract][Full Text] [Related]
19. Complement receptor is an inhibitor of the complement cascade.
Iida K; Nussenzweig V
J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
[TBL] [Abstract][Full Text] [Related]
20. A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b.
Meri S; Pangburn MK
Eur J Immunol; 1990 Dec; 20(12):2555-61. PubMed ID: 2148521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
